ArsenalBio logo

Arsenal Biosciences, Inc.


ArsenalBio Stock

ArsenalBio is a biotechnology company that is focused on developing next-generation cell therapies for the treatment of cancer. ArsenalBio's proprietary technology platform, called "Deep-Genomics," uses artificial intelligence and machine learning to identify and analyze genetic targets in cancer cells. This platform enables the company to design and develop highly targeted cell therapies that can be customized to meet the unique needs of individual patients.

Management Team

Kenneth Drazan Co-Founder, Chief Executive Officer
Tarjei Mikkelsen, Ph.D. Chief Technology Officer
Susie Jun, Ph.D. Chief Medical Officer
Nick Haining Co-Founder, Chief Scientific Officer
Bee Nguyen Chief People Officer
Tim Sirichoke Chief Technology Operations Officer

Funding Information


ArsenalBio Named to Endpoints 11 List as One of the Top Biotechs of 2023 • Arsenal Bio

ArsenalBio announced that it has been named to the Endpoints 11, one of the 11 top biotechs of 2023. This is an annual honor selected by the editors of Endpoints News for the most promising and ambitious early-stage companies in the biotech industry.

ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual Meeting • Arsenal Bio

ArsenalBio announced that it will present preclinical data on its ICT cell therapies, AB-1015 and AB-2100, in an oral abstract session and three posters at the American Society of Gene and Cell Therapy (ASGCT) annual meeting in Los Angeles, Calif., May 16-20, 2023.

ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable Cell Therapy Progress • Arsenal Bio

ArsenalBio announced the presentation of six abstracts at the American Association for Cancer Research (AACR) annual meeting in Orlando, Fla., April 14-19, 2023. These data demonstrate the company’s continued progress towards the enhancement and clinical development of its unique integrated circuit T cell approach for diseases beyond ovarian cancer, including kidney cancer and other solid tumors.

Arsenal Biosciences Announces Joint Discovery Collaboration with Genentech to Identify Features of Successful T-Cell Therapies for Oncology • Arsenal Bio

ArsenalBio announced a multi-year collaboration with Genentech, a member of the Roche Group. The companies will deploy ArsenalBio’s proprietary technology for high-throughput screening and engineering of T cells, to identify critical success circuits in T cell-based therapies.

Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development • Arsenal Bio

ArsenalBio announced the close of a $220 million Series B financing round.